Genes & Diseases' 2026 Journal Metrics Score is 2.0, ranking Q3 in Molecular Biology and 1 other subfield. Two-year citation average from OpenAlex data, updated August 2026.
Bookmark this page — track observed submission-to-acceptance timing, FWCI and field-normalized citation data for this journal in one view.
Journal Metrics Score 2026 · 2021–2024 window citedness 4.91.
Middle 50%: 99–186 days
100 of 100 PubMed-indexed articles · 100% coverage · 2024–2025
No journal-level APC is available in the current OpenAlex snapshot. Cost is excluded from scoring.
Paste your title to see which of this journal's published topics it overlaps with. Your title stays in your browser for this preview and is not sent anywhere.
Want ranked journals with fit reasons, risks and a submission strategy instead? See a sample AI report.
Each spoke is a 0–100 percentile within a comparable journal cohort—not a percentage grade or a single black-box rating.
158 of 1,000 works · same type, year & subfield
14 works · same type, year & subfield
Below field-year expectation
of 1,351 topic-associated OpenAlex sources by lifetime output
FWCI compares papers with the same publication year, type, and field. 1.0 is the world average; above 1.0 is above expectation. This journal's median is 0.69, so its typical recent paper runs about 31% below its field benchmark.
15.8% of recent papers rank in the global top 10% after field normalization. This is easier to compare across specialties than raw citation totals.
Volume is separated from citation accumulation so newer papers are not presented as weaker simply because they are newer.
OpenAlex source records · 2016–2025
1,000 OpenAlex works · 2021–2024
OpenAlex topics show the research communities this journal serves.
Candidates share at least one OpenAlex subfield (or field, if too few do) with this journal's main research topics, ignoring generic catch-all topics, and are ordered by topic overlap, then current Journal Metrics Score.
* Cost is indicative only. APCs, taxes, waivers, and member discounts can change—always verify on the journal's official website.
| Category | Quartile |
|---|---|
| Molecular Biology | Q3 |
| Cancer Research | Q3 |
Confirm the exact title and ISSNs against the publisher homepage before a high-stakes submission decision.
Source: the current OpenAlex source record. OpenAlex works can include multiple work types. Fully Open Access is a source-level flag. Recent OA Works is summed from OpenAlex's counts_by_year series (up to the latest ten years); it is not a lifetime OA percentage. Any APC shown here is an indicative OpenAlex value—verify current charges on the journal's official website.
Genes & Diseases' 2026 Journal Metrics Score is 2.0, from the August 2026 data release. The score is a two-year citation average computed from OpenAlex (CC0) data: citations received in the most recent complete year to works published in the two prior years, divided by the number of those works.
Genes & Diseases' best quartile is Q3. By OpenAlex subfield: Q3 in Molecular Biology; Q3 in Cancer Research. Quartiles rank journals by Journal Metrics Score within each subfield.
No. Journal Metrics computes the score independently from OpenAlex open data. Other providers use different citation databases, document types, and counting rules, so their published figures for Genes & Diseases will not match this score exactly. Compare journals using one source at a time.
Across 100 recent PubMed records with both dates, Genes & Diseases took a median of 124 days from submission to acceptance; the middle half took 99–186 days. This interval includes editorial handling and revisions, so it is not the time to a first decision.
Comparable journals include International Journal of Oncology, International Journal of Biological Sciences, Cell Death & Disease, and Cellular Signalling. Compare their scores, acceptance times, and costs in the recommended alternatives on this page before choosing where to submit.